News

The acquisition bolsters LGC’s growing portfolio of reference materials and proficiency testing (PT) schemes for the clinical market. LGC’s Standards Division managing director Euan O’Sullivan said: "We are

The primary endpoint of this study is progression free survival (PFS). Duvelisib is an oral, dual inhibitor of phosphoinositide-3-kinase (PI3K)-delta and PI3K-gamma. Infinity is jointly developing duvelisib with

Immune CEO Daniel Teper said: "We recently announced U.S. IND acceptance by the FDA for bertilimumab in bullous pemphigoid, and today, with our first patient enrollment in ulcerative

The PAREXEL Clinical Development Optimization process uses advanced technology to help expedite drug development through all four critical stages of clinical development – design, start-up, trial execution, and

Kalydeco has also been approved to use in CF patients at least 18 years old and more who have an R117H mutation. Vertex had earlier secured approval to

Helsinn Healthcare together with Roche Palo Alto filed an infringement lawsuit against Teva Pharmaceuticals USA and Teva Pharmaceutical Industries (collectively Teva) in the US. The US District Court

The Phase I/IIa trial, which is anticipated to start in the first half of 2016, will be funded and carried out by the NCI on about 55 patients.

The extension will run until November 2019 with an option to add another year. Summit will retain the exclusive rights to any intellectual property resulting from the alliance.

Roche’s option stems from a pre-existing deal with Novartis. Ophthotech’s agreement with Novartis, which was signed in May last year, remains in effect. Ophthotech retains exclusive rights to